Trial Profile
Study of Risk Factors of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With a Direct Oral Anticoagulant (Rivaroxaban)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Thromboembolism
- Focus Adverse reactions
- Acronyms EMIR
- Sponsors Bayer
- 17 Aug 2021 According to a Bayer media release, results from this trial will be presented European Society of Cardiology (ESC) Congress 2021.
- 29 Oct 2020 Status changed from active, no longer recruiting to completed.
- 26 May 2020 Planned End Date changed from 30 May 2020 to 30 Sep 2020.